Are Cronos Group insiders buying or selling stock?
In the past three months, Cronos Group insiders have not sold or bought any company stock. Only 5.52% of the stock of Cronos Group is held by insiders. Only 12.45% of the stock of Cronos Group is held by institutions. Earnings for Cronos Group are expected to grow in the coming year, from ($0.37) to ($0.31) per share.
What did Cronos Group (Cron) announce?
Canadian cannabis company Cronos Group (NASDAQ: CRON) promoted John Griese, former chief operating officer of The Supreme Cannabis Co., as senior vice president, head of North American operations, *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Is Cronos Group the safest pot Stock?
When he's not out hunting for cheap stocks or writing articles, odds are he's writing macros in Excel or reading history books. Cronos Group ( NASDAQ:CRON) has been one of the safer pot stocks to invest in, if for no other reason than it is backed by tobacco giant Altria, which owns a 45% stake in the business.
What does Cronos do for a living?
Cronos Group, Inc. engages in the production and distribution of cannabis. Its brands include PEACE NATURALS, COVE, Spinach, Lord Jones, and PEACE+. The company was founded by Lorne Michael Gertner and Paul Rosen on August 21, 2012 and is headquartered in Toronto, Canada.
/https://specials-images.forbesimg.com/imageserve/1159774334/0x0.jpg%3FcropX1%3D0%26cropX2%3D6000%26cropY1%3D308%26cropY2%3D3683)
Will Cronos stock go back up?
The 10 analysts offering 12-month price forecasts for Cronos Group Inc have a median target of 3.49, with a high estimate of 8.45 and a low estimate of 2.96. The median estimate represents a +21.55% increase from the last price of 2.87.
Why is Cronos stock going up?
Shares of global cannabis company Cronos Group (CRON -5.77%) rocketed higher on Tuesday after the company reported its earnings for the first three months of 2022. The company missed Wall Street's earnings per share (EPS) estimates, but investors were happy with its solid growth numbers.
Is CRON a good stock to buy now?
The financial health and growth prospects of CRON, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Is Cronos a sell?
Cronos Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 4 hold ratings, and 2 sell ratings.
Is Cronos a good buy 2021?
There's potential for Cronos stock to soar if its cultivated products prove to be the difference-makers that management expects them to be. But for now, this pot stock remains an ultra-risky buy.
Does Cronos have a future?
DigitalCoinPrice supported the positive cronos (CRO/USD) forecast but saw a much slower pace of growth in future years. The site expected that the CRO token could reach $0.27 by the end of 2022, $0.39 by the end of 2024 and $0.41 by 2025.
What sector is CRON stock?
Description. Cronos Group Inc. operates as a cannabinoid company.
Is CGC a buy or sell?
Today CGC ranks #18543 as sell candidate.
Is VRME a good stock to buy?
The consensus among 1 Wall Street analyst covering (NASDAQ: VRME) stock is to Strong Buy VRME stock.
What is Cronos Crypto?
Cronos is a utility token for the Crypto.com platform. Users can get fee discounts by paying with CRO and also stake the tokens to qualify for benefits. These include higher interest rates on deposits and better benefits on the Crypto.com prepaid debit cards. The more CRO staked, the better the rewards.
Does Cronos Group pay Dividends?
Does Cronos Group pay a dividend? Does it plan to? The Company does not pay a dividend.
How much is Cronos?
The current price is $1.145192 per CRONO.
Should I buy or sell Cronos Group stock right now?
8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 2 sel...
What is Cronos Group's stock price forecast for 2022?
8 Wall Street analysts have issued twelve-month target prices for Cronos Group's stock. Their forecasts range from $3.00 to $6.00. On average, they...
How has Cronos Group's stock price performed in 2022?
Cronos Group's stock was trading at $3.92 on January 1st, 2022. Since then, CRON shares have decreased by 30.4% and is now trading at $2.73. View...
When is Cronos Group's next earnings date?
Cronos Group is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for Cronos Gr...
How were Cronos Group's earnings last quarter?
Cronos Group Inc. (NASDAQ:CRON) posted its earnings results on Tuesday, May, 10th. The company reported ($0.09) EPS for the quarter, missing analys...
Who are Cronos Group's key executives?
Cronos Group's management team includes the following people: Mr. Michael Ryan Gorenstein J.D. , Pres, CEO & Chairman (Age 35, Pay $389.15k) ( L...
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Tilray (TLRY) , Canopy Growth (CGC) , USANA Health Sciences (USNA) , Cresco Labs (CRLBF...
What other stocks do shareholders of Cronos Group own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include (CGC) , Aurora Cannab...
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
Is Cronos stock a Buy, Sell or Hold?
Cronos stock has received a consensus rating of hold. The average rating score is and is based on 0 buy ratings, 3 hold ratings, and 2 sell ratings.
What was the 52-week low for Cronos stock?
The low in the last 52 weeks of Cronos stock was 2.80. According to the current price, Cronos is 108.21% away from the 52-week low.
What was the 52-week high for Cronos stock?
The high in the last 52 weeks of Cronos stock was 9.42. According to the current price, Cronos is 32.17% away from the 52-week high.
What are analysts forecasts for Cronos stock?
The 5 analysts offering price forecasts for Cronos have a median target of 4.00, with a high estimate of 5.50 and a low estimate of 3.00. The media...
How much does Cronos Group make?
Is Cronos Group a hold?
Cronos Group has a market capitalization of $2.66 billion and generates $46.72 million in revenue each year. The company earns $-73,140,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis.
Is Cronos a US company?
Wall Street analysts have given Cronos Group a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cronos Group wasn't one of them.
Does Cronos own Pharmacann?
Cronos Group ( NASDAQ: CRON) has been chomping at the bit to get into the U.S. market. Although the company makes the bulk of its money in Canada, it includes that in its "rest of world" segment. The company has been launching hemp-based products in the U.S. for the sake of penetrating the market.
Who is Al Harrington?
Canadian pot producer Cronos Group on Monday announced an arrangement to invest in PharmaCann, a large multistate cannabis company in the U.S. Cronos stock and other marijuana stocks fell. Under the deal, Cronos — whose higher-ups already have connections with PharmaCann — said a subsidiary had purchased an option to acquire around 10.5% of the U.S. company, which runs marijuana production facilities and dispensaries across six states. The option, Cronos said, would be exercised based on various factors, "including the status of U.S. federal cannabis legalization, as well as regulatory approvals, including in the states where PharmaCann operates that may be required upon exercise."
What happened
Al Harrington, CEO & Co-Founder of Viola and Randy Osei, Founder & CEO of Athlete Tech Group , joins Yahoo Finance to discuss the new mentorship program Rising Star to help Black Canadian youth in the tech sector and diversity in the cannabis space.
So what
Shares of Cronos Group ( CRON -2.10% ) slumped 14% in December, according to data provided by S&P Global Market Intelligence. The cannabis producer got dragged down by the broad market sell-off in cannabis stocks last month and has yet to file its third-quarter report with the U.S. Securities and Exchange Commission (SEC).
Now what
Cronos Group has put out some surprising announcements recently, starting in November when it stated that it would be unable to file its 10-Q quarterly report on time with the SEC for the period ending in September 2021.
Premium Investing Services
Since going public in 2017, Cronos Group stock is up over 2,200%. But over the last six months, it is actually down slightly over 50%, leading to some tough losses for anyone that bought the stock in 2021. The company has also never gotten close to profitability, burning almost $200 million in cash over the past 12 months.
NASDAQ: CRON
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What happened
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
So what
Shares of Cronos Group ( CRON 3.90% ) are tumbling 16.5% in morning trading Tuesday after the Canadian marijuana company filed a form 12b-25 with the Securities and Exchange Commission saying it would be unable to file its quarterly earnings report on time.
NASDAQ: CRON
It was just yesterday that its shares were soaring on speculation that Altria would acquire the pot stock .
Now what
The tobacco giant invested $1.8 billion in Cronos in 2019 in exchange for a 45% stake in the company, but Altria has itself been writing down the value of that investment over time.
Premium Investing Services
In 2019 Cronos acquired Redwood Holding for $300 million to gain access to its Lord Jones brand of CBD-infused lotions, gummies, bath salts, and oils.
What company did Cronos buy?
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
What is the advantage of Cronos?
Lab-grown products have been on Cronos' radar for a while. In 2018, it acquired biotech company Ginkgo Bioworks for $122 million with the goal of creating cultured cannabinoids. And now, it appears that day is swiftly approaching.
Is Cronos lab grown?
For Cronos, this is an exciting development -- if there is no difference to the consumer, these products could make the company a lot more competitive. The big advantage is that Cronos could make lab-grown products for pennies per gram. And keeping costs down is essential in order to compete with the black market.
When will Cronos earnings be released?
According to Bloomberg, Cronos Executive Chairman Mike Gorenstein expects that his company will have lab-grown cannabis products available as early as this year. The products would be the first of their kind for the industry. And although it would be a different way of making cannabis, he says that the tetrahydrocannabinol (THC) or cannabidiol (CBD) would be the same as what producers are making today, stating that, "the cannabinoids are the same whether they're coming from the plant or from fermentation."
Is Cronos still trading?
In its most recent earnings release on Nov. 5, 2020, sales of $11.4 million for the period ending Sept. 30, 2020 were double what Cronos generated a year ago. But that still doesn't change the fact that the company still has a long way to go to catch up to its peers. Cronos stock could soar if its lab-grown products hit ...
Is Aurora Cannabis a Tilray?
Given its low market share, Cronos is still trading at a very high price-to-sales (P/S) multiple compared to the stocks mentioned above: CRON PS Ratio data by YCharts. The good news is that the ratio can come down in a hurry if Cronos is able to build on its recent growth.
Is Cronos stock a guarantee?
Aurora Cannabis launched the "Daily Special" last year, while Tilray, which is merging with Aph ria, offers consumers "The Batch," which its Chief Marketing Officer Adine Fabiani-Carter called "a new no-frills cannabis brand focused on delivering quality cannabis flower and pre-rolls at competitive prices.".
The cannabis company is facing a host of challenges
Cronos stock could soar if its lab-grown products hit the market this year and become a hit with consumers. But that's by no means a guarantee. With a high valuation and too many question marks surrounding its business, the stock is far from a sure thing right now.
What happened
Joe honed his investing skills as an analyst for Stock Advisor. He battle-tested his investment philosophy and strategies as portfolio manager of Tier 1, a market-crushing Motley Fool real-money portfolio that delivered 24.58% annualized returns.
So what
Shares of Cronos Group ( NASDAQ:CRON) sank 15.9% on Thursday, following the marijuana producer's disappointing second-quarter results.
Now what
Cronos Group's net revenue climbed 29% year over year to $9.9 million. The gains were driven by the launch of cannabis vaporizers in Canada, as well as sales of Lord Jones cannabidiol ( CBD) products, a brand Cronos acquired in September. Still, these results fell short of analysts' estimates, which had called for revenue of $12.7 million.
